# SKB264-II-06 (NCT05642780)

> SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05642780
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Klus Pharma Inc.
- Conditions: Solid Tumor
- Interventions: SKB264; Pembrolizumab
- Enrollment: 240
- Primary outcome: Dose limiting toxicity (DLT) and adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Prostate-specific antigen (PSA) response rate (Cohort D)

## Indexed commentary on SKB264-II-06 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=skb264-ii-06-nct05642780

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05642780", "email": "<work email>"}; the inbox owner confirms by the emailed link.